Tuberculosis disease (TD) is caused by the activation of latent TB infection (LTBI). LTBI is noninfectious and asymptomatic but can be treated to reduce the probability of progression to disease. With over 15 million persons in the United States infected with LTBI, prioritizing high risk groups for LTBI testing and treatment is essential to feasibly and cost effectively controlling the spread of TB. This dissertation comprises three essays that will help policymakers decide who, how and why to test and treat for LTBI.
This document was submitted as a dissertation in June 2015 in partial fulfillment of the requirements of the doctoral degree in public policy analysis at the Pardee RAND Graduate School. The faculty committee that supervised and approved the dissertation consisted of Emmett Keeler (Chair), Shanthi Nataraj, and Ricardo Basurto-Davila.
This report is part of the RAND Corporation Dissertation series. Pardee RAND dissertations are produced by graduate fellows of the Pardee RAND Graduate School, the world's leading producer of Ph.D.'s in policy analysis. The dissertations are supervised, reviewed, and approved by a Pardee RAND faculty committee overseeing each dissertation.
This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited; linking directly to this product page is encouraged. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial purposes. For information on reprint and reuse permissions, please visit www.rand.org/pubs/permissions.
The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.